10097-ACT-6 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPAN
Noriyuki Kijima(The University of Osaka), Haruhiko Kishima(Osaka University Hospital), Koki Murakami(The University of Osaka), Naoki Kagawa(The University of Osaka), Ryuichi Hirayama(The University of Osaka), Satoru Oshino(The University of Osaka), Takuto Emura(The University of Osaka), Koichi Hosomi(RELX Group (Netherlands)), Takahiro Matsuhashi(The University of Osaka), Yoshiko Okita(The University of Osaka), Manabu Kinoshita(Brigham and Women's Hospital), Manabu Kanemoto, Reina Utsuki(The University of Osaka), Tetsuro Tachi(The University of Osaka), Hideki Kuroda(The University of Osaka), Naoki Tani(Osaka Gakuin University)
Cited by 1
Related Papers
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruption
|Proceedings of the National Academy of Sciences|2006|648
PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria
|Nature Communications|2012|599
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
|The Lancet|2014|436
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|369
MEIOSIN Directs the Switch from Mitosis to Meiosis in Mammalian Germ Cells
|Developmental Cell|2020|211